Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


29.03.2021

1 AJR Am J Roentgenol
2 BJU Int
1 BMC Urol
3 Cancer
2 Cancer Res
1 Clin Cancer Res
2 Int J Radiat Oncol Biol Phys
2 Invest Radiol
2 J Nucl Med
4 N Engl J Med
3 Nat Rev Urol
1 Oncogene
1 Oncol Rep
1 PLoS One
1 Proc Natl Acad Sci U S A
3 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. SATISH P, Emberton M, Norris JM
    Tumor Topography for Diagnosis of Prostate Cancer.
    AJR Am J Roentgenol. 2021 Mar 24:W1. doi: 10.2214/AJR.20.25410.
    PubMed        


    BJU Int

  2. MARSHALL CH, Tunacao J, Danda V, Tsai HL, et al
    Reversing the effects of androgen deprivation therapy in men with metastatic castration resistant prostate cancer.
    BJU Int. 2021 Mar 25. doi: 10.1111/bju.15408.
    PubMed         Abstract available

  3. ANING JJ, Parry MG, van der Meulen J, Fowler S, et al
    How reliable is surgeon reported data? : A comparison of the British Association of Urological Surgeons radical prostatectomy audit with the National Prostate Cancer Audit Hospital Episode Statistic linked database.
    BJU Int. 2021 Mar 22. doi: 10.1111/bju.15399.
    PubMed         Abstract available


    BMC Urol

  4. WANG J, Xie S, Liu J, Li T, et al
    MicroRNA-4429 suppresses proliferation of prostate cancer cells by targeting distal-less homeobox 1 and inactivating the Wnt/beta-catenin pathway.
    BMC Urol. 2021;21:40.
    PubMed         Abstract available


    Cancer

  5. HIGANO CS, Armstrong AJ, Sartor O, Vogelzang NJ, et al
    Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
    Cancer. 2020;126:2935-2937.
    PubMed        

  6. DORES GM, Niu MT, Izurieta HS
    Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
    Cancer. 2020;126:2934-2935.
    PubMed        

  7. CARAM MEV, Burns J, Kumbier K, Sparks JB, et al
    Factors influencing treatment of veterans with advanced prostate cancer.
    Cancer. 2021 Mar 25. doi: 10.1002/cncr.33485.
    PubMed         Abstract available


    Cancer Res

  8. CARRENO DV, Corro NB, Cerda-Infante JF, Echeverria CE, et al
    Dietary Fructose Promotes Prostate Cancer Growth.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-19-0456.
    PubMed         Abstract available

  9. SHI L, Yan Y, He Y, Yan B, et al
    Mutated SPOP E3 ligase promotes 17betaHSD4 protein degradation to drive androgenesis and prostate cancer progression.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-20-3258.
    PubMed         Abstract available


    Clin Cancer Res

  10. VARDAKI I, Corn P, Gentile E, Song JH, et al
    Radium 223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4790.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  11. MAGLI A, Farneti A, Faiella A, Ferriero M, et al
    Toxicity at 1 year after Stereotactic Body Radiotherapy in 3 Fractions for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 18. pii: S0360-3016(21)00287.
    PubMed         Abstract available

  12. FOLKERT MR, Zelefsky MJ, Hannan R, Desai NB, et al
    A Multi-Institutional Phase II Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 19. pii: S0360-3016(21)00285.
    PubMed         Abstract available


    Invest Radiol

  13. ESSER M, Zinsser D, Kundel M, Lingg A, et al
    Performance of an Automated Workflow for Magnetic Resonance Imaging of the Prostate: Comparison With a Manual Workflow.
    Invest Radiol. 2020;55:277-284.
    PubMed         Abstract available

  14. TOKUDA J, Wang Q, Tuncali K, Seethamraju RT, et al
    Temperature-Sensitive Frozen-Tissue Imaging for Cryoablation Monitoring Using STIR-UTE MRI.
    Invest Radiol. 2020;55:310-317.
    PubMed         Abstract available


    J Nucl Med

  15. BUCKNOR MD, Hope T
    Reply: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center".
    J Nucl Med. 2021 Mar 19. pii: jnumed.121.262332. doi: 10.2967/jnumed.121.262332.
    PubMed        

  16. AFAQ A, Payne H, Davda R, Hines J, et al
    A Phase II, Open-label study to assess safety and management change using (68)Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study.
    J Nucl Med. 2021 Mar 19. pii: jnumed.120.257527. doi: 10.2967/jnumed.120.257527.
    PubMed         Abstract available


    N Engl J Med

  17. HUSSAIN M, Desai C, de Bono J
    Olaparib in Metastatic Castration-Resistant Prostate Cancer. Reply.
    N Engl J Med. 2021;384:1175-1176.
    PubMed        

  18. BISWAS B, Ganguly S, Ghosh J
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1174-1175.
    PubMed        

  19. MCCAW ZR, Liu MA, Wei LJ
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1174.
    PubMed        

  20. SMITH TJ
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1175.
    PubMed        


    Nat Rev Urol

  21. SCHMIDT KT, Huitema ADR, Chau CH, Figg WD, et al
    Resistance to second-generation androgen receptor antagonists in prostate cancer.
    Nat Rev Urol. 2021 Mar 19. pii: 10.1038/s41585-021-00438.
    PubMed         Abstract available

  22. NG SWS, Wyatt AW
    Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer.
    Nat Rev Urol. 2021 Mar 19. pii: 10.1038/s41585-021-00455.
    PubMed        

  23. SRIVASTAVA A, Shore ND
    Combined advanced prostate cancer treatments: are they additive?
    Nat Rev Urol. 2021 Mar 23. pii: 10.1038/s41585-021-00459.
    PubMed        


    Oncogene

  24. ZHOU J, Wang Y, Wu D, Wang S, et al
    Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.
    Oncogene. 2021 Mar 9. pii: 10.1038/s41388-021-01737.
    PubMed         Abstract available


    Oncol Rep

  25. PEREZ G, Lopez-Moncada F, Indo S, Torres MJ, et al
    Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells.
    Oncol Rep. 2021;45.
    PubMed         Abstract available


    PLoS One

  26. LIMA CA, da Silva BEB, Hora EC, Lima MS, et al
    Trends in prostate cancer incidence and mortality to monitor control policies in a northeastern Brazilian state.
    PLoS One. 2021;16:e0249009.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  27. XU L, Yin Y, Li Y, Chen X, et al
    A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


    Prostate

  28. GRAHAM LS, True LD, Gulati R, Schade GR, et al
    Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24118.
    PubMed         Abstract available

  29. CHOI Y, Smith KC, Shukla A, Blackford AL, et al
    What are survivorship care plans failing to tell men after prostate cancer treatment?
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24116.
    PubMed         Abstract available

  30. SABOL RA, Ledet EM, Jaeger E, Hatton W, et al
    Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Prostate. 2021 Mar 24. doi: 10.1002/pros.24120.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: